DrugPatentWatch Database Preview

RYTARY Drug Patent Profile

Email this page to a colleague

« Back to Dashboard

When do Rytary patents expire, and when can generic versions of Rytary launch?

Rytary is a drug marketed by Impax Labs Inc and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-eight patent family members in fourteen countries.

The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rytary

A generic version of RYTARY was approved as carbidopa; levodopa by MAYNE PHARMA on August 28^th, 1992.

Summary for RYTARY

International Patents:	38
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Patent Applications:	33
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for RYTARY
Drug Sales Revenues:	Drug sales revenues for RYTARY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYTARY
What excipients (inactive ingredients) are in RYTARY?	RYTARY excipients list
DailyMed Link:	RYTARY at DailyMed

See drug prices for RYTARY

See drug sales revenues for RYTARY

Pharmacology for RYTARY

Drug Class

Aromatic Amino Acid

Anatomical Therapeutic Chemical (ATC) Classes for RYTARY

N04BA	Dopa and dopa derivatives
N04B	DOPAMINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for RYTARY

Tradename	Dosage	Ingredient	NDA	Submissiondate
RYTARY	CAPSULE, EXTENDED RELEASE;ORAL	carbidopa; levodopa	203312	2015-06-24
RYTARY	CAPSULE, EXTENDED RELEASE;ORAL	carbidopa; levodopa	203312	2015-06-10

US Patents and Regulatory Information for RYTARY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-002	Jan 7, 2015		RX	Yes	No			Y
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes			Y
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No			Y		Y
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes			Y
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes			Y
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes			Y
Impax Labs Inc	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No			Y

International Patents for RYTARY

Country	Patent Number	Estimated Expiration
Australia	2008343787
Japan	2011507956
European Patent Office	1507518
Taiwan	200633730
China	101910113
South Korea	20100099731
World Intellectual Property Organization (WIPO)	03101432